Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma
NCT03995706Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sacituzumab govitecan in breast cancer and glioblastoma (GBM), sponsored by UT Health San Antonio. Primary endpoint: Ratio of SN-38 and its metabolites relative to serum concentration. Started Jul 2019; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancerglioblastoma (GBM)
Beyond the preview
Go deeper on NCT03995706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995706.